Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer:
We previously reported a sentinel lymph node biopsy positivity rate of 2% in patients with cN0, TNBC and Her2+ breast cancer who achieved an excellent breast response to NST on MRI, suggesting that omission of SLNB may be safe in this setting.
The findings of the present study are fully aligned with those of our prior publication with a SLNB positivity rate below 10% in cN0 ER negative disease.”
Title: Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
Authors: Munaser Alamoodi, Umar Wazir, Kinan Mokbel, Neill Patani, Jajini Varghese, Kefah Mokbel
You can read the full article in MDPI Cancers.
Title: Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy
Authors: Florien J. G. van Amstel, Rik G. M. van Mierlo, Patty J. Nelemans, Sanne M. E. Engelen, Janneke Houwers, Loes F. S. Kooreman, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, Marjolein L. Smidt, Thiemo J. A. van Nijnatten
You can read the full article in European Radiology.
More posts featuring Kefah Mokbel.